+

WO2003006495A3 - Human papillomavirus e2 transactivation domain/inhibitor co-crystal and x-ray coordinates defining the inhibitor-binding pocket - Google Patents

Human papillomavirus e2 transactivation domain/inhibitor co-crystal and x-ray coordinates defining the inhibitor-binding pocket Download PDF

Info

Publication number
WO2003006495A3
WO2003006495A3 PCT/CA2002/001058 CA0201058W WO03006495A3 WO 2003006495 A3 WO2003006495 A3 WO 2003006495A3 CA 0201058 W CA0201058 W CA 0201058W WO 03006495 A3 WO03006495 A3 WO 03006495A3
Authority
WO
WIPO (PCT)
Prior art keywords
inhibitor
tad
hpv
complex
binding pocket
Prior art date
Application number
PCT/CA2002/001058
Other languages
French (fr)
Other versions
WO2003006495A2 (en
Inventor
Dale R Cameron
Jacques Archambault
Christiane Yoakim
Peter White
Original Assignee
Boehringer Ingelheim Int
Dale R Cameron
Jacques Archambault
Christiane Yoakim
Peter White
Wang Yong
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to MXPA04000271A priority Critical patent/MXPA04000271A/en
Priority to DK02745024T priority patent/DK1409525T3/en
Priority to CA2448482A priority patent/CA2448482C/en
Priority to DE60215658T priority patent/DE60215658T2/en
Priority to JP2003512265A priority patent/JP4602665B2/en
Priority to HU0402069A priority patent/HUP0402069A3/en
Priority to NZ531068A priority patent/NZ531068A/en
Priority to EP02745024A priority patent/EP1409525B1/en
Priority to AU2002317122A priority patent/AU2002317122B2/en
Priority to IL15915002A priority patent/IL159150A0/en
Application filed by Boehringer Ingelheim Int, Dale R Cameron, Jacques Archambault, Christiane Yoakim, Peter White, Wang Yong filed Critical Boehringer Ingelheim Int
Publication of WO2003006495A2 publication Critical patent/WO2003006495A2/en
Publication of WO2003006495A3 publication Critical patent/WO2003006495A3/en
Priority to IL159150A priority patent/IL159150A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Laminated Bodies (AREA)

Abstract

A crystallizable composition, comprising an PV E2 TAD-like polypeptide of SEQ ID NO.2 complexed with an inhibitor L. The invention also provides a method for producing the crystallized HPV E2 TAD-inhibitor complex (HPV E2 TAD-L) comprising: a) mixing purified HPV E2 TAD, contained in a purification buffer, with solublized inhibitor L to generate a complex solution containing the HPV E2 TAD-L complex; and b) crystallizing the complex from a) in a crystallization buffer. The invention also provides a method for producing crystallized apo HPV E2 TAD, comprising: a) mixing apo HPV E2 TAD, contained in a purification buffer, with a crystallization buffer.X-ray crystal structure coordinates the HPV E2 TAD-L complex, are also provided, which define an inhibitor binding pocket. The inhibitor binding pocket is useful for screening potential small molecule inhibitors that bind to the pocket.
PCT/CA2002/001058 2001-07-12 2002-07-12 Human papillomavirus e2 transactivation domain/inhibitor co-crystal and x-ray coordinates defining the inhibitor-binding pocket WO2003006495A2 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
AU2002317122A AU2002317122B2 (en) 2001-07-12 2002-07-12 Human papillomavirus E2 transactivation domain/inhibitor co-crystal and x-ray coordinates defining the inhibitor-binding pocket
CA2448482A CA2448482C (en) 2001-07-12 2002-07-12 Human papillomavirus e2 transactivation domain/inhibitor co-crystal and x-ray coordinates defining the inhibitor-binding pocket
DE60215658T DE60215658T2 (en) 2001-07-12 2002-07-12 TWIN CRYSTAL OF HUMAN PAPILLOMAVIRUS E2 TRANSACTION DOMAIN AND AN INHIBITOR AND ROENTGEN STRUCTURE COORDINATES DEFINING THE INHIBITOR BINDING BAG
JP2003512265A JP4602665B2 (en) 2001-07-12 2002-07-12 X-ray coordinates defining the human papillomavirus E2 transactivation domain / inhibitor co-crystal and the inhibitor binding pocket
HU0402069A HUP0402069A3 (en) 2001-07-12 2002-07-12 Human papillomavirus e2 transactivation domain/inhibitor co-crystal and x-ray coordinates defining the ihnibitor-binding pocket
MXPA04000271A MXPA04000271A (en) 2001-07-12 2002-07-12 Human papillomavirus e2 transactivation domain/inhibitor co-crystal and x-ray coordinates defining the inhibitor-binding pocket.
EP02745024A EP1409525B1 (en) 2001-07-12 2002-07-12 Human papillomavirus e2 transactivation domain/inhibitor co-crystal and x-ray coordinates defining the inhibitor-binding pocket
NZ531068A NZ531068A (en) 2001-07-12 2002-07-12 Human papillomavirus E2 transactivation domain/inhibitor co-crystal and x-ray coordinates defining the inhibitor-binding pocket
IL15915002A IL159150A0 (en) 2001-07-12 2002-07-12 Human papillomavirus e2 transactivation domain/inhibitor co-crystal and x-ray coordinates defining the inhibitor-binding pocket
DK02745024T DK1409525T3 (en) 2001-07-12 2002-07-12 Human papillomavirus E2 transactivation domain / inhibitor co-crystal and X-ray coordinates defining the inhibitory binding pocket
IL159150A IL159150A (en) 2001-07-12 2003-12-02 Human papillomavirus e2 transactivation domain/inhibitor co-crystal and method for its production

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30441201P 2001-07-12 2001-07-12
US60/304,412 2001-07-12

Publications (2)

Publication Number Publication Date
WO2003006495A2 WO2003006495A2 (en) 2003-01-23
WO2003006495A3 true WO2003006495A3 (en) 2003-07-31

Family

ID=23176405

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2002/001058 WO2003006495A2 (en) 2001-07-12 2002-07-12 Human papillomavirus e2 transactivation domain/inhibitor co-crystal and x-ray coordinates defining the inhibitor-binding pocket

Country Status (14)

Country Link
US (1) US7167801B2 (en)
EP (2) EP1695980B1 (en)
JP (1) JP4602665B2 (en)
AT (2) ATE343588T1 (en)
AU (1) AU2002317122B2 (en)
CA (1) CA2448482C (en)
DE (2) DE60215658T2 (en)
DK (2) DK1409525T3 (en)
ES (2) ES2342309T3 (en)
HU (1) HUP0402069A3 (en)
IL (2) IL159150A0 (en)
MX (1) MXPA04000271A (en)
NZ (1) NZ531068A (en)
WO (1) WO2003006495A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1627323A4 (en) * 2003-05-06 2008-04-09 New Century Pharmaceuticals Albumin binding sites for evaluating drug interactions and methods of evaluating or designing drugs based on therir albumin binding properties
DE602004023939D1 (en) * 2003-05-26 2009-12-17 Biotie Therapies Corp CRYSTALLINE VAP-1 AND USE
US20070043509A1 (en) * 2003-11-03 2007-02-22 Carter Daniel C Albumin binding sites for evaluating drug interactions and methods of evaluating or designing drugs based on their albumin binding properties
US20090118301A1 (en) * 2007-11-02 2009-05-07 Arbor Vita Corporation Compositions and Methods for Treating Cancer
CN112891520A (en) * 2021-04-13 2021-06-04 吉林省国大生物工程有限公司 Preparation method of active biological protein for preventing and controlling Human Papilloma Virus (HPV) infection

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5620849A (en) * 1991-10-11 1997-04-15 Cetus Corporation Methods and compositions for identifying inhibitors of papilloma virus replication
EP0969013A1 (en) * 1998-06-30 2000-01-05 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Peptides for inhibiting HPV E7 proteins
WO2001021645A2 (en) * 1999-09-17 2001-03-29 The University Of York Target for antiviral therapy
WO2002050082A2 (en) * 2000-12-18 2002-06-27 Boehringer Ingelheim (Canada) Ltd. Inhibitors of papilloma virus

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0101396A3 (en) 1998-05-01 2006-03-28 Boehringer Ingelheim Ca Ltd Preparation of human papillomavirus e1 having helicase activity and method therefor
WO2000075182A1 (en) * 1999-06-04 2000-12-14 Akira Kaji Crystal of ribosomal recycling factor (rrf) protein and application thereof on the basis of three-dimensional structural data obtained from the crystal
CA2389569A1 (en) * 1999-11-16 2001-05-25 Vertex Pharmaceuticals Incorporated Crystallizable compositions comprising a caspase-7

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5620849A (en) * 1991-10-11 1997-04-15 Cetus Corporation Methods and compositions for identifying inhibitors of papilloma virus replication
EP0969013A1 (en) * 1998-06-30 2000-01-05 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Peptides for inhibiting HPV E7 proteins
WO2001021645A2 (en) * 1999-09-17 2001-03-29 The University Of York Target for antiviral therapy
WO2002050082A2 (en) * 2000-12-18 2002-06-27 Boehringer Ingelheim (Canada) Ltd. Inhibitors of papilloma virus

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KIM SS ET AL.: "The Structural Basis of DNA Target Discrimination by Papillomavirus E2 Proteins", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 275, no. 40, 6 October 2000 (2000-10-06), pages 31245 - 31254, XP002238197 *

Also Published As

Publication number Publication date
ES2342309T3 (en) 2010-07-05
HUP0402069A3 (en) 2012-09-28
ATE465414T1 (en) 2010-05-15
IL159150A0 (en) 2004-06-01
EP1409525A2 (en) 2004-04-21
HUP0402069A2 (en) 2005-01-28
US7167801B2 (en) 2007-01-23
ES2274051T3 (en) 2007-05-16
CA2448482A1 (en) 2003-01-23
DK1695980T3 (en) 2010-08-02
NZ531068A (en) 2006-06-30
EP1409525B1 (en) 2006-10-25
WO2003006495A2 (en) 2003-01-23
US20030082769A1 (en) 2003-05-01
DE60236114D1 (en) 2010-06-02
JP2005512954A (en) 2005-05-12
MXPA04000271A (en) 2005-03-07
JP4602665B2 (en) 2010-12-22
EP1695980B1 (en) 2010-04-21
EP1695980A3 (en) 2006-09-06
DK1409525T3 (en) 2007-02-05
DE60215658D1 (en) 2006-12-07
IL159150A (en) 2009-09-01
DE60215658T2 (en) 2007-12-27
AU2002317122B2 (en) 2007-03-15
ATE343588T1 (en) 2006-11-15
EP1695980A2 (en) 2006-08-30
CA2448482C (en) 2011-12-06

Similar Documents

Publication Publication Date Title
AU662142B2 (en) Phenyl amidines derivatives useful as platelet aggregation inhibitors
DE50312257D1 (en) (METH) ACRYLIC ACID CRYSTAL AND METHOD FOR THE PRODUCTION AND PURIFICATION OF WAFERRIGER (METH) ACRYLIC ACID
WO2004043339A3 (en) Substituted cycloalkyl p1' hepatitis c virus inhibitors
EA200401139A1 (en) HIGHLY SILICA SHABAZIT, ITS SYNTHESIS AND ITS APPLICATION IN TRANSFORMING OXYGEN SUBSTANCES TO OLEFINS
AU2003299519A1 (en) Hepatitis c virus inhibitors
BR9909358A (en) Compound, pharmaceutical composition, and, process to prevent or alleviate chronic complications resulting from diabetes mellitus
BRPI0410685B8 (en) 1,3-propanediol purification processes and composition
ES2194202T3 (en) POLYMORPH COMPOUNDS.
AU2002350191A1 (en) Substituted heteroarylalkanoic acids and their use as aldose reductase inhibitors
BR0015836A (en) 4-carboxyamino-2-ethyl-1,2,3,4-tetrahydroquinoline crystal as cetp inhibitor
ATE299029T1 (en) METHODS AND COMPOSITIONS FOR PEPTIDE SYNTHESIS (T-20)
ATE255124T1 (en) METHOD FOR OBTAINING PHYTOSTEROLS BY CRYSTALLIZATION FROM REDUCED QUANTITIES OF METHANOL
DE60331891D1 (en) CRYSTALLINE COMPLEXES OF FLUTICASONE 2-FUROAT
WO2003006495A3 (en) Human papillomavirus e2 transactivation domain/inhibitor co-crystal and x-ray coordinates defining the inhibitor-binding pocket
DE60131423D1 (en) RAT SPECIFIC CATHEPSIN, DIPEPTIDYL PEPTIDASE I (DPPI): CRYSTAL STRUCTURE, INGREDIENTS AND ITS APPLICATIONS
RU94000064A (en) New 2-cyano-3-hydroxypropeneamides, method of preparing thereof, and pharmaceutical compositions containing said compounds
Walton et al. The association of different urinary proteins with calcium oxalate hydromorphs. Evidence for non-specific interactions
AU4304596A (en) A process for the preparation of substituted 4-ethyl-piperidines and an intermediate for the preparation of same
EP1772461A4 (en) CRYSTALLINE OR CRYSTAL LACTOSUCROSIS CONTAINING MOLLASSES CONTAINING SAID COMPOUND INSIDE AND USE THEREOF
NZ516235A (en) Method for purification of proteins
Ricci Jr et al. The crystal and molecular structure of bestatin and its implications regarding substrate binding to the active site of leucine aminopeptidase
EA200601641A1 (en) CRYSTAL COMPOSITION CONTAINING ESCYTAL PREMAX OXALATE
TR200503398T1 (en) New crystal forms of trandolapril.
JP2004506047A5 (en)
PT1462439E (en) Novel stable crystals of substituted phenylpropionic acid derivative and process for producing the same

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2448482

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 159150

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: PA/a/2004/000271

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2003512265

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2002745024

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2002317122

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 531068

Country of ref document: NZ

WWP Wipo information: published in national office

Ref document number: 2002745024

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 2002745024

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 2002317122

Country of ref document: AU

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载